Skip to main content


Quality Outlook

DiscernBreakthrough treatments in cancer care, including precision therapies tailored to specific patient factors, are driving rapid changes in the definitions of oncology quality and value. Efforts to implement value-based care models in oncology must meet the demands of evolving science, new best care practices, and shifting patient priorities. Quality measures must be up-to-date and relevant. Payment models must recognize the challenges and costs of managing complex patient populations with diverse needs. In this JCP commentary series, Quality Outlook, Discern Health will explore key issues in oncology quality and value through posts focused on measurement, value-based payment, and quality improvement.

Discern Health is a consulting firm that works with clients across the private and public sectors to improve health and health care through quality-based payment and delivery models. These models align performance with incentives by rewarding doctors, hospitals, suppliers, and patients for working together to improve health care while lowering total costs.

ValuckTom Valuck is the main contributor to Quality Outlook and a Partner at Discern Health. He is a thought leader on health care system transformation and helps lead the firm’s focus on achieving better health and health care outcomes at a lower cost. Tom’s work at Discern includes facilitating the exploration of next-generation measurement and accountability models for health care delivery systems. He also helps clients develop strategies to achieve success within the value-based marketplace.

Blog
Tom Valuck, MD, JD—Blog Editor; David Blaisdell; Theresa Schmidt, MA, PMP, CSPO February 09, 2021
In this blog, Tom Valuck, MD, JD, and colleagues explore ways for CMS to incorporate telehealth in oncology alternative payment models.
Blog
Tom Valuck, MD, JD—Blog Editor; David Blaisdell; Theresa Schmidt, MA, PMP, CSPO, February 09, 2021
In this blog, Tom Valuck, MD, JD, and colleagues explore ways for CMS to incorporate telehealth in oncology alternative…
Blog
Tom Valuck, MD, JD—Blog Editor; Theresa Schmidt, MA, PMP, CSPO; David Blaisdell; Manasi Tirodkar, PhD, MS, January 11, 2021
Tom Valuck, MD, JD, and colleagues explore social media as a data source for bringing patient voices into quality…
Blog
Tom Valuck, MD, JD—Blog Editor; David Blaisdell; Manasi A Tirodkar, PhD, MS, May 27, 2020
Tom Valuck, MD, JD, and colleagues shed light on the value of indirect benefits of effective cancer care and challenges…
Blog
Tom Valuck, MD, JD; Theresa Schmidt, MA, PMP, CSPO; David Blaisdell; Manasi Tirodkar, PhD, MS, March 24, 2020
Tom Valuck, MD, JD, and colleagues explore whether patient-reported measure sets and patient-reported performance…
Blog
Tom Valuck, MD, JD—Blog Editor; Manasi A Tirodkar, PhD, MS; David Blaisdell, January 24, 2020
Tom Valuck, MD, JD, and colleagues of Discern Health argue that if the Oncology Care First model proposed by CMS is…
Blog
Tom Valuck, MD, JD—Blog Editor; David Blaisdell; Theresa Schmidt, MA, PMP, CSPO, November 22, 2019
Tom Valuck, MD, JD, and colleagues of Discern Health highlight the challenge that physicians face with integrating…
Blog
Tom Valuck, MD, JD—Blog Editor; David Blaisdell; Manasi A Tirodkar, PhD, MS, September 18, 2019
In the first installment of the Quality Outlook commentary series, Tom Valuck, MD, JD, Discern Health, and colleagues…
Back to Top